• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 14, 2018

View Archived Issues

Upcoming Website Maintenance

Due to website maintenance this weekend, there could be periodic outages starting Friday evening through Sunday. We apologize for any inconvenience. Read More

Other news to note

Crown Biosciences Inc., of San Diego, published preclinical data in the Journal of the National Cancer Institute in conjunction with Carsgen Therapeutics Ltd., of Shanghai, and the Shanghai Cancer Institute showing CLDN18.2 targeting CAR T cells can eliminate gastric tumors in a PDX mouse model. Read More

Financings

Galapagos NV, of Mechelen, Belgium, said it priced its U.S. public offering totaling $300 million gross proceeds from the sale of 2.575 million new ordinary shares in the form of American depositary shares (ADSs) at $116.50 each. In addition, the company has granted the underwriters an option to purchase up to an additional 386,266 ADSs. Read More

Regulatory front

The FDA released a batch of 54 draft product-specific guidances Thursday to help sponsors identify appropriate science-based methodologies and evidence for developing generic drugs.  Read More

Clinical data for Sept. 13, 2018

Read More

Australia's Cellmid nears clinic with midkine antibodies

PERTH, Australia – Cellmid Ltd.'s lead anti-midkine antibody, CAB-102, reduced kidney injury and preserved renal function in a preclinical model of focal segmental glomerulosclerosis (FSGS), according to studies performed at the Westmead Institute in New South Wales. Read More

DTC ad bill falls in House-Senate budget conference despite bipartisan support

Members of the U.S. Senate and House of Representatives met Thursday to hash out a budget bill for a number of agencies, including the NIH, but an amendment dealing with drug prices in direct-to-consumer (DTC) ads failed to draw enough support to be reinserted into the appropriations bill. The matter is ended for now, but the concept enjoys bipartisan support on Capitol Hill and the support of the Trump administration, which has opened a docket number for drug price transparency. Read More

Moleculin's STAT3 inhibitor begins dosing in MD Anderson-led phase I study

"We've finally pushed open a door to an entirely new pathway of potential approaches to treat cancer," Walter Klemp, chair and CEO of Moleculin Biotech Inc., said about the initiation of an investigator-led phase I study of STAT3 inhibitor WP-1066 in glioblastoma at MD Anderson Cancer Center. "People have been pounding on this door for a long time, and it was painful getting here, but now it's opened." Read More

One small step could lead the way to savings at the pharmacy . . . and future steps

Vowing it's only the first step in tackling skyrocketing drug prices in the U.S., the House Energy and Commerce Committee unanimously voted Thursday to favorably report to the House floor a bill banning gag clauses that prevent pharmacists from discussing cheaper payment options with insured customers. Read More

BMS psoriasis results highlight distinct appeal of Tyk2 target

A positive phase II readout for Bristol-Myers Squibb Co.'s lead oral tyrosine kinase 2 (Tyk2) inhibitor in plaque psoriasis has shone a new light on signaling pathways explored by few drugmakers to date. Despite the pathway's implication in multiple immune-mediated diseases, the phase III program BMS is actively enrolling for patients with moderate to severe plaque psoriasis puts it at the head of a cohort that includes just two other clinical-stage drugs of the class – both Pfizer Inc.'s – and only four discovery-stage assets, according to Cortellis. Read More

Astrazeneca's Lumoxiti wins FDA nod for hairy cell leukemia

Cambridge, U.K.-based Astrazeneca plc and its Medimmune unit will introduce the first new drug for hairy cell leukemia (HCL) in more than two decades, with the FDA's approval Thursday for Lumoxiti (moxetumomab pasudotox-tdfk). The CD22-targeted cytotoxin is indicated for adults with relapsed or refractory disease who have received at least two prior systemic therapies, including a purine nucleoside analogue. Read More

PD PDUFA stammer: FDA wants more time to mull Acorda's Inbrija package

Days after a court decision torpedoed four patents protecting Acorda Therapeutics Inc.'s Ampyra (dalfampridine) – clearing the way for generic versions of the only drug approved in the U.S. for improving walking in people with multiple sclerosis – the company learned that the FDA has extended the PDUFA date for its NDA related to Inbrija (levodopa inhalation powder) to treat off-period symptoms in people with Parkinson's disease (PD) on a carbidopa/levodopa regimen. Read More

Boehringer triggers Viratherapeutics option in $245M buyout for oncolytic virus firm

DUBLIN – Another big gun has entered the oncolytic virus fray. Prompted by positive progress in its collaboration with Viratherapeutics GmbH, Boehringer Ingelheim GmbH has exercised an option to buy the company outright in a deal worth €210 million (US$245 million) in total. Read More

Regulatory actions for Sept. 13, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe